Compounds > acetylglucosamine
Page last updated: 2024-08-22

acetylglucosamine and alpha-synuclein

acetylglucosamine has been researched along with alpha-synuclein in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (66.67)24.3611
2020's4 (33.33)2.80

Authors

AuthorsStudies
Abeywardana, T; Cherwien, CA; Marotta, NP; Pratt, MR1
Ambroso, MR; Arnold, DB; Langen, R; Lewis, YE; Lin, YH; Marotta, NP; Pratt, MR; Roth, MT; Zaro, BW1
El-Agnaf, OM; Kawasaki, I; Kim, DK; Lee, HJ; Lee, SJ; Lim, HS; Shim, YH; Vaikath, NN1
Brennan, CK; De Leon, CA; Galesic, A; Lamiri, N; Levine, PM; Lewis, YE; Pratt, MR1
Balana, A; De Leon, CA; Galesic, A; Levine, PM; Lewis, YE; Marotta, NP; Pratt, MR1
Craven, TW; De Leon, CA; Levine, PM; Pratt, MR1
Kalia, LV; Kalia, SK; O'Hara, DM1
Balana, AT; De Leon, CA; Galesic, A; Lashuel, HA; Levine, PM; Mahul-Mellier, AL; Navarro, MX; Pratt, MR1
Davey, AK; Kassiou, M; Mellick, GD; Rudrawar, S; Ryan, P; Xu, MM1
Galesic, A; Pratt, MR1
Balana, AT; Cutolo, G; Galesic, A; Moon, SP; Pacheco, RP; Pratt, MR; Rakshit, A1
Balana, AT; Pratt, MR1

Reviews

2 review(s) available for acetylglucosamine and alpha-synuclein

ArticleYear
Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
    British journal of pharmacology, 2018, Volume: 175, Issue:15

    Topics: Acetylglucosamine; Adrenergic beta-Agonists; alpha-Synuclein; Animals; Gastrointestinal Microbiome; Humans; Parkinson Disease

2018
Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.
    The Biochemical journal, 2021, 07-30, Volume: 478, Issue:14

    Topics: Acetylglucosamine; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Glycosylation; Humans; N-Acetylglucosaminyltransferases; Parkinson Disease; Protein Processing, Post-Translational; tau Proteins

2021

Other Studies

10 other study(ies) available for acetylglucosamine and alpha-synuclein

ArticleYear
O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation.
    Chembiochem : a European journal of chemical biology, 2012, Dec-21, Volume: 13, Issue:18

    Topics: Acceleration; Acetylglucosamine; alpha-Synuclein; Amino Acid Sequence; Glycosylation; Peptide Fragments; Protein Multimerization; Protein Structure, Secondary

2012
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease.
    Nature chemistry, 2015, Volume: 7, Issue:11

    Topics: Acetylglucosamine; Acylation; alpha-Synuclein; Humans; Parkinson Disease

2015
Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function.
    Autophagy, 2016, 10-02, Volume: 12, Issue:10

    Topics: Acetylglucosamine; Aging; alpha-Synuclein; Animals; Caenorhabditis elegans; Disease Models, Animal; Endosomes; Humans; Lysosomes; Mutation; Polyubiquitin; Protein Aggregates; Transgenes; Ubiquitination

2016
O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.
    ACS chemical biology, 2017, 04-21, Volume: 12, Issue:4

    Topics: Acetylglucosamine; Acylation; alpha-Synuclein; Cell Membrane; Escherichia coli; Protein Binding; Serine

2017
O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
    Bioorganic & medicinal chemistry, 2017, 09-15, Volume: 25, Issue:18

    Topics: Acetylglucosamine; alpha-Synuclein; Calpain; Escherichia coli; Humans; Parkinson Disease; Peptides; Protein Processing, Post-Translational; Proteolysis; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization

2017
The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.
    Biochemistry, 2017, 07-11, Volume: 56, Issue:27

    Topics: Acetylglucosamine; alpha-Synuclein; Animals; beta-N-Acetylhexosaminidases; Circular Dichroism; Computational Biology; Humans; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Peptide Fragments; Protein Folding; Protein Processing, Post-Translational; Protein Stability; Recombinant Proteins; Serine; Substrate Specificity; Threonine

2017
α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 01-29, Volume: 116, Issue:5

    Topics: Acetylglucosamine; Acylation; alpha-Synuclein; Animals; Cells, Cultured; Female; Mice; Mice, Inbred C57BL; Parkinson Disease; Pregnancy; Protein Aggregation, Pathological; Protein Processing, Post-Translational

2019
O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation.
    Bioorganic chemistry, 2020, Volume: 94

    Topics: Acetylglucosamine; alpha-Synuclein; Carbohydrate Conformation; Dose-Response Relationship, Drug; Glycosylation; Humans; Parkinson Disease; Protein Aggregates; Structure-Activity Relationship

2020
Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
    Methods in molecular biology (Clifton, N.J.), 2020, Volume: 2133

    Topics: Acetylglucosamine; alpha-Synuclein; Cysteine; Escherichia coli; Esters; Gene Expression; Glycosylation; Humans; Parkinson Disease; Peptide Biosynthesis; Peptides; Plasmids; Protein Engineering; Recombinant Proteins; Solid-Phase Synthesis Techniques; Sulfhydryl Compounds; Threonine

2020
Comparison of
    ACS chemical biology, 2021, 01-15, Volume: 16, Issue:1

    Topics: Acetylglucosamine; alpha-Synuclein; Carbohydrate Conformation; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Monosaccharides; Spectrometry, Mass, Electrospray Ionization

2021